Intensity Therapeutics(INTS) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update First patient dosed in randomized, Phase 2 study in presurgical triple negative breast cancer Shelton, Conn., November 13, 2024 – Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune s ...